亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

作者
Ravi Vij,Henning Helmut Schade,S. Trudel,A. C. Chang,J. Huang,D. Samineni,T. Sumiyoshi,Jia-An Tsai,T. Wong,S. J. Harrison
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:6: 1905-1906 被引量:1
标识
DOI:10.1097/01.hs9.0000850968.59423.24
摘要

Background: Treatment of relapsed/refractory (R/R) multiple myeloma (MM) is challenging, especially in later lines where drug resistance reduces therapeutic options and remission duration. Prognosis is poor (estimated survival: <1 year) for patients with MM who have received >3 prior lines of therapy and are triple refractory to immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs) and anti-CD38 agents (Gandhi et al. 2019). Thus R/R MM constitutes a significant unmet medical need. Fragment crystallizable receptor-like 5 (FcRH5) is expressed on myeloma cells with near 100% prevalence (Li et al. 2017), constituting a novel therapeutic target. Cevostamab is an IgG1-based T-cell-engaging bispecific antibody engineered to target the most membrane-proximal domain of FcRH5 on myeloma cells and cluster of differentiation 3 (CD3) on T-cells, resulting in T-cell killing of myeloma cells. Clinical data from the first-in-human Phase I study (GO39775) suggest that cevostamab monotherapy is highly active in heavily pre-treated patients with R/R MM, with an overall response rate of 56.7% at the 132–198mg dose level (Trudel et al. ASH 2021 Oral presentation). Thus, cevostamab’s activity and safety profile support further development. Due to their stimulatory effects on T-cell activity, combination of cevostamab with anti-myeloma agents (pomalidomide [P] or daratumumab [D]) may be synergistic, offering the potential to further improve efficacy. Aims: To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of cevostamab-containing combination regimens (Arm B: cevostamab plus P and dexamethasone [d] [Pd]; Arm C: cevostamab plus Dd) in patients with R/R MM. A modified weekly schedule for cevostamab is also under investigation (Arm A: cevostamab monotherapy). Methods: CAMMA 1 (NCT04910568) is an open-label, multicentre Phase Ib trial in patients with R/R MM. Patients must be aged ≥18 years, have an Eastern Cooperative Oncology Group Performance Status of 0 or 1 and a life expectancy of >12 weeks. Patients in all arms have R/R MM; Arms B and C include patients with prior IMiD and PI exposure. Patients with prior CAR-T therapy may enroll with a washout period of 12 weeks post-CAR-T infusion. Cevostamab is administered by intravenous infusion q1w (C1–2)/q2w (C3–6)/q4w (C7–13) in Arm A, q2w (C1–6)/q4w (C7+) in Arm B, and q3w (C1–8)/q4w (C9+) in Arm C. Each arm consists of a safety run-in and an expansion cohort. The primary objective is to evaluate the safety and tolerability of cevostamab plus Pd, cevostamab plus Dd and cevostamab monotherapy. Secondary objectives include assessment of activity, PK, immunogenicity, and pharmacodynamic biomarkers. Results: Enrolment for Arm A is ongoing, with patients receiving up to 13 treatment cycles. Arms B and C are planned; patients will receive treatment until disease progression or unacceptable toxicity. All patients must provide informed consent. Summary/Conclusion: CAMMA 1 is an ongoing study of cevostamab plus Pd, cevostamab plus Dd and cevostamab monotherapy in patients with R/R MM. Further study details will be presented.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
成就马里奥完成签到,获得积分10
6秒前
8秒前
11秒前
纯情的阁发布了新的文献求助10
14秒前
22秒前
深情的从丹完成签到,获得积分10
26秒前
30秒前
阿丕啊呸完成签到,获得积分10
35秒前
38秒前
39秒前
null的应助被伊比利亚的微风采纳,获得10
40秒前
认真的笑卉完成签到,获得积分10
41秒前
49秒前
aba发布了新的文献求助10
55秒前
hamburger完成签到,获得积分10
58秒前
null的应助被等待若魔采纳,获得10
1分钟前
陶醉成协完成签到,获得积分10
1分钟前
haralee完成签到 ,获得积分10
1分钟前
1分钟前
乐正元正完成签到,获得积分10
1分钟前
时尚的蜜蜂完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
1分钟前
Logan1001发布了新的文献求助10
1分钟前
1分钟前
1分钟前
bkagyin的应助被Logan1001采纳,获得10
1分钟前
hyman发布了新的文献求助10
1分钟前
1分钟前
1分钟前
生动琦完成签到,获得积分10
2分钟前
彩色的可冥完成签到,获得积分10
2分钟前
Logan1001完成签到,获得积分20
2分钟前
2分钟前
从容煜城完成签到,获得积分10
2分钟前
2分钟前
顺利秋天完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354